CNS & Neurological Disorders-Drug Targets

Scope & Guideline

Advancing the Frontiers of Neurological Research

Introduction

Explore the comprehensive scope of CNS & Neurological Disorders-Drug Targets through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore CNS & Neurological Disorders-Drug Targets in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1871-5273
PublisherBENTHAM SCIENCE PUBL
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCNS NEUROL DISORD-DR / CNS Neurol. Disord.-Drug Targets
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 294, BUSUM 1400 AG, NETHERLANDS

Aims and Scopes

The journal "CNS & Neurological Disorders-Drug Targets" focuses on advancing the understanding and treatment of neurological disorders through innovative drug targets and therapeutic strategies. It encompasses a wide range of topics related to the central nervous system (CNS) and emphasizes the integration of pharmacological, biochemical, and molecular approaches to tackle neurological diseases.
  1. Pharmacological Research:
    The journal emphasizes pharmacological studies on various compounds, including natural products, synthetic drugs, and biologics, aimed at understanding their mechanisms of action in treating neurological disorders.
  2. Neurodegenerative Disorders:
    A significant focus is placed on neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS), exploring novel therapeutic targets and treatment paradigms.
  3. Neuroinflammation and Neuroprotection:
    Research related to neuroinflammation and neuroprotective strategies is a core area, addressing the role of immune responses and potential therapeutic interventions to mitigate neuroinflammatory damage.
  4. Neuropsychiatric Disorders:
    The journal also covers neuropsychiatric conditions, investigating the interplay between neurological and psychiatric symptoms, treatment efficacy, and new pharmacological approaches.
  5. Innovative Drug Delivery Systems:
    There is a keen interest in exploring novel drug delivery systems, including nanotechnology and transdermal systems, to enhance the efficacy of treatments for CNS disorders.
  6. Molecular Mechanisms and Biomarkers:
    The journal promotes research on molecular mechanisms underlying neurological disorders, including the identification of biomarkers for early diagnosis and monitoring of therapeutic responses.
The journal has been adapting to the latest advancements in neuroscience and pharmacology, leading to the emergence of several trending themes that are gaining traction in recent publications. These themes reflect the evolving landscape of neurological research and therapeutic strategies.
  1. Microbiome-Gut-Brain Axis:
    Recent studies have highlighted the significance of the microbiome-gut-brain axis in neurological disorders, indicating a growing interest in how gut health influences brain function and disease progression.
  2. Neuroinflammation as a Therapeutic Target:
    There is an increasing focus on neuroinflammation and its role in various neurological conditions, with research exploring anti-inflammatory strategies as potential therapeutic approaches.
  3. Nanotechnology in Drug Delivery:
    Emerging research on nanotechnology for drug delivery systems is gaining momentum, showcasing innovative methods to enhance the bioavailability and efficacy of treatments for CNS disorders.
  4. Genetic and Epigenetic Research:
    Investigations into genetic and epigenetic factors influencing neurological disorders are on the rise, emphasizing personalized medicine and targeted therapeutic interventions.
  5. Artificial Intelligence and Machine Learning:
    The integration of artificial intelligence and machine learning in analyzing neurological data is becoming a prominent theme, aiding in diagnosis, treatment planning, and outcome prediction.
  6. Phytochemicals and Natural Products:
    There is a renewed interest in the therapeutic potential of phytochemicals and natural products, with research focusing on their mechanisms of action and efficacy in neurological conditions.

Declining or Waning

While the journal continuously evolves with emerging research themes, certain topics have seen a decline in publication frequency or focus. These waning scopes may reflect shifting interests in the field or advancements in alternative therapeutic strategies.
  1. Traditional Herbal Medicine:
    The interest in traditional herbal remedies as standalone treatments has diminished, possibly due to an increasing focus on evidence-based pharmacological approaches and the need for standardized treatment protocols.
  2. Basic Animal Models:
    The reliance on basic animal models for studying neurological diseases appears to be waning, as there is a growing emphasis on more sophisticated models that better replicate human conditions and disease mechanisms.
  3. Single Agent Studies:
    Research focusing solely on the efficacy of single-agent therapies is declining, with a shift towards combination therapies that address the multifactorial nature of neurological disorders.
  4. Epidemiological Studies:
    There seems to be a reduction in the publication of purely epidemiological studies, as the journal increasingly prioritizes studies that integrate clinical findings with molecular and pharmacological research.

Similar Journals

Journal of Neuroimmune Pharmacology

Exploring the Intersection of Neuroscience and Pharmacology
Publisher: SPRINGERISSN: 1557-1890Frequency: 4 issues/year

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

International Journal of Molecular and Cellular Medicine

Elevating Understanding in Molecular and Cellular Medicine
Publisher: CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTERISSN: 2251-9637Frequency: 4 issues/year

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Frontiers in Molecular Neuroscience

Unraveling the complexities of neuroscience, one molecule at a time.
Publisher: FRONTIERS MEDIA SAISSN: 1662-5099Frequency: 1 issue/year

Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

CURRENT DRUG TARGETS

Unraveling the Complexities of Drug Action
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

ACTA NEUROPATHOLOGICA

Transforming Understanding of Neurological Disorders
Publisher: SPRINGERISSN: 0001-6322Frequency: 12 issues/year

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

Fluids and Barriers of the CNS

Connecting Researchers to the Frontiers of Neurophysiology
Publisher: BMCISSN: 2045-8118Frequency: 1 issue/year

Fluids and Barriers of the CNS is a premier open-access journal published by BMC, dedicated to advancing the field of neuroscience by exploring the complexities of the fluid dynamics and barriers of the central nervous system. Since its inception in 2011, the journal has established itself as a vital resource for researchers, professionals, and students alike, providing a platform for innovative research and critical discussions in areas such as cellular and molecular neuroscience, developmental neuroscience, neurology, and miscellaneous medicine. With an impressive Q1 ranking across multiple categories in 2023, and strong performance metrics such as being ranked in the 93rd percentile in Developmental Neuroscience, this journal not only highlights cutting-edge research but also contributes to the ongoing dialogue surrounding neurophysiology and pathology. As an open-access journal based in London, United Kingdom, it ensures that high-quality research is accessible to a global audience, fostering collaboration and knowledge-sharing in the neuroscientific community.

Current Neuropharmacology

Unraveling the complexities of neuropharmacology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Neurology-Neuroimmunology & Neuroinflammation

Championing open access to critical neuroimmunology findings.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2332-7812Frequency: 6 issues/year

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

NEUROMOLECULAR MEDICINE

Illuminating the Path to Neurotherapeutic Breakthroughs
Publisher: HUMANA PRESS INCISSN: 1535-1084Frequency: 4 issues/year

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Neurochemical Journal

Exploring the Frontiers of Neurochemistry
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1819-7124Frequency: 4 issues/year

Neurochemical Journal, published by MAIK NAUKA/INTERPERIODICA/SPRINGER, focuses on the dynamic and rapidly evolving field of neurochemistry, providing insights into cellular and molecular neuroscience. Despite the discontinuation of its coverage in Scopus, the journal remains a valuable resource for researchers and professionals seeking to explore the biochemical underpinnings of neural function and pathophysiology. With an ISSN of 1819-7124 and an E-ISSN of 1819-7132, the journal aims to publish rigorous research articles, reviews, and notes that push the boundaries of our understanding of neurochemical processes. With a ranking that places its subjects in the lower quartile of their respective fields, Neurochemical Journal offers a platform for innovative studies and discussions among up-and-coming scientists, making it a crucial outlet for advancing the discourse in this critical area of biomedical research.